

EUROBIO SCIENTIFIC LAUNCHES THE EXCLUSIVE DISTRIBUTION OF THE FIRST SALIVA SELF-TEST FOR HIV TESTING IN FRANCE

OraQuick®: first rapid saliva self-test for HIV screening for point-of-care biology, including pharmacies

Paris, January 11, 2022 – 5:45pm

Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in specialty in vitro medical diagnostics, announces that it entered into an exclusive distribution contract for the commercialization of OraQuick®, a saliva self-test, with Orasure, a US company. This exclusive contract includes the French market and its overseas territories.

OraQuick® is a CE marked rapid test that can detect the presence of antibodies characteristic of HIV infections in 20 minutes from a saliva sample. Like the COVID serological tests, it includes a small plate with a window to view the result. It does not require a blood sample but a simple saliva sample drawn with a palette also provided for this purpose.

In France, an estimated 173,000 people are infected with HIV, 24,000 of whom are unaware of their infection. Currently, more than 25% of HIV tests are carried out on late stage infections. The availability of rapid screening tests that are easy to implement is therefore essential to encourage self-screening in all discretion.

OraQuick® is immediately available in pharmacies and for hospital or non-profit organizations screening centers. With this test, Eurobio Scientific is strengthening its presence in point-of-care biology, particularly in pharmacies, and expanding its range of self-tests, its COVID self-test being already available since June 2021.

Next financial meeting

2021 FY revenues: 24 January 2022

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 164 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

For more information, please visit : www.eurobio-scientific.com

The company is publicly listed on the Euronext Growth market in Paris

Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

Contacts

Group Eurobio Scientific

Denis Fortier, General Manager
Hervé Duchesne de Lamotte, General Manager
Tel. +33(0) 1 69 79 64 80

Calyptus

Mathieu Calleux / Gregory Bosson
Investors relations
Tel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net